SG11201604944PA - Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features - Google Patents

Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Info

Publication number
SG11201604944PA
SG11201604944PA SG11201604944PA SG11201604944PA SG11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA SG 11201604944P A SG11201604944P A SG 11201604944PA
Authority
SG
Singapore
Prior art keywords
vortioxetine
kappa
activity
treatment
receptor antagonist
Prior art date
Application number
SG11201604944PA
Other languages
English (en)
Inventor
Connie Sanchez Morillo
Gennady N Smagin
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52146489&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201604944P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of SG11201604944PA publication Critical patent/SG11201604944PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201604944PA 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features SG11201604944PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300710 2013-12-20
DKPA201400590 2014-10-16
PCT/EP2014/078515 WO2015091833A1 (fr) 2013-12-20 2014-12-18 Utilisation d'un antagoniste du récepteur opioïde présentant une activité kappa et de vortioxétine dans le traitement de trouble dépressif avec caractéristiques mélancoliques

Publications (1)

Publication Number Publication Date
SG11201604944PA true SG11201604944PA (en) 2016-07-28

Family

ID=52146489

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201604944PA SG11201604944PA (en) 2013-12-20 2014-12-18 Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features

Country Status (14)

Country Link
US (1) US10376506B2 (fr)
EP (1) EP3082815B1 (fr)
JP (1) JP6448645B2 (fr)
KR (1) KR20160093025A (fr)
CN (1) CN105828821B (fr)
AU (1) AU2014368548B2 (fr)
CA (1) CA2933733A1 (fr)
CL (1) CL2016001570A1 (fr)
ES (1) ES2694352T3 (fr)
IL (1) IL246253A0 (fr)
MX (1) MX368870B (fr)
RU (1) RU2679661C1 (fr)
SG (1) SG11201604944PA (fr)
WO (1) WO2015091833A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026728A1 (fr) 2016-07-01 2018-01-04 H. Lundbeck A/S Schemas posologiques de la vortioxetine destines a une apparition rapide de l'effet antidepresseur
EP3876938A4 (fr) 2018-11-06 2022-08-10 Purdue Pharma L.P. Compositions et procédés d'administration d'antagoniste opioïde
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013740A (en) 1990-03-22 1991-05-07 Hillel Glover Method for treating emotional numbness and coma
US5028612A (en) 1990-03-22 1991-07-02 Hillel Glover Method for treating emotional numbness
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
EP1353665A4 (fr) * 2000-12-21 2004-05-06 Mclean Hospital Corp Traitement de la depression
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20030153590A1 (en) * 2001-08-14 2003-08-14 Oy Contral Pharma Ltd Method of treating alcoholism or alcohol abuse
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
JP2005528359A (ja) * 2002-03-20 2005-09-22 ユーロ−セルティーク エス．エイ． うつ病の治療のためのブプレノルフィンの投与方法
US20080045610A1 (en) * 2004-09-23 2008-02-21 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP2009517393A (ja) * 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2008066916A1 (fr) 2006-11-30 2008-06-05 The Mclean Hospital Corporation Procédés de traitement de troubles de l'humeur
DE502007002185D1 (de) * 2006-04-04 2010-01-14 Emodys Gmbh Verwendung von zusammensetzungen enthaltend kappa-opioidrezeptor-antagonisten zur behandlung von dissoziativen störungen
US20070259939A1 (en) * 2006-05-04 2007-11-08 Accelerated Technologies Using naltrexone as a multi-purpose health supplement to improve the human condition and preventing multiple diseases and infirmities by stimulating immune system vitality and robustness
MX2008016141A (es) 2006-06-16 2009-02-04 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)-fenil] piperazina como un compuesto con actividad combinada de recaptación de serotonina, 5-ht3 y 5-ht1a.para el tratamiento de daño cognitivo.
TW200848411A (en) 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
RS54599B1 (en) 2009-05-25 2016-08-31 H. Lundbeck A/S PREPARATION OF NALMEPHEN HYDROCHLORIDE FROM NALTREXONE
WO2011020030A2 (fr) * 2009-08-13 2011-02-17 The General Hospital Corporation Procédés et compositions pour empêcher la dépendance
MY162392A (en) 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
EP2635586B1 (fr) 2010-11-05 2017-02-08 H. Lundbeck A/S Procédé pour la fabrication de naltrexone
CA2899455C (fr) * 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Traitement de la depression et autres maladies avec un agent a faible dose
CA2909506C (fr) 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene pour le traitement de patients atteints de trouble de l'anxiete
CA2909504C (fr) * 2013-04-17 2021-04-20 H. Lundbeck A/S Nalmefene pour le traitement de patients atteints de trouble de l'humeur

Also Published As

Publication number Publication date
MX368870B (es) 2019-10-21
EP3082815A1 (fr) 2016-10-26
EP3082815B1 (fr) 2018-10-03
KR20160093025A (ko) 2016-08-05
ES2694352T3 (es) 2018-12-20
US10376506B2 (en) 2019-08-13
CL2016001570A1 (es) 2016-12-09
IL246253A0 (en) 2016-07-31
US20160310488A1 (en) 2016-10-27
WO2015091833A1 (fr) 2015-06-25
CN105828821A (zh) 2016-08-03
JP2016540030A (ja) 2016-12-22
JP6448645B2 (ja) 2019-01-09
RU2016123972A (ru) 2018-01-25
MX2016007947A (es) 2016-09-09
AU2014368548B2 (en) 2019-09-19
CN105828821B (zh) 2019-04-09
RU2679661C1 (ru) 2019-02-12
AU2014368548A1 (en) 2016-06-30
CA2933733A1 (fr) 2015-06-25

Similar Documents

Publication Publication Date Title
HUS2200048I1 (hu) FcRn antagonisták és alkalmazásaik
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
HK1216380A1 (zh) 附接裝置以及使用和製造的相關聯的方法
HK1217428A1 (zh) 取代的苯並噁唑及其使用方法
SI2970473T1 (sl) Kombinacija dr5 agonista in anti-pd-1 antagonista in postopek uporabe
HK1213476A1 (zh) 取代的三唑並吡啶及其使用方法
HUE062312T2 (hu) Hordozható berendezés és eljárás hordozható berendezés használatának korlátozására
IL252547A0 (en) Treatment of multiple sclerosis using laquinimod
EP2989538A4 (fr) Procédé et dispositif pour la gestion de mémoire de dispositif utilisateur
EP2971292A4 (fr) Appareil de filage électrostatique et procédés de son utilisation
PL2837591T3 (pl) Przyrząd przewlekający snowarskiej ramy natykowej i sposób jego użycia
HK1224307A1 (zh) 原毒素- 變體及其使用方法
HK1218254A1 (zh) 用拉喹莫德治療多發性硬化症
SG11201507276UA (en) Improved methods of use for recombinant human secretoglobins
IL246253A0 (en) Use of an opioid receptor antagonist with kappa activity and vortioxetine for the treatment of depressive disorder with melancholic features
EP3013344A4 (fr) Traitement d'une arrythmie à l'aide d'un antagoniste des opioïdes
GB201302105D0 (en) Cover Means and Method of Use Thereof